Ocugen, Inc. (OCGN)

Trade OCGN now with
1/9/2023 6:24:53 AM Ocugen Announces Positive Top-Line Data For COVID-19 Vaccine Candidate COVAXIN In Phase 2/3 Immuno-bridging And Broadening Study
12/16/2022 6:41:40 AM Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement For NeoCart
9/1/2022 7:37:35 AM Ocugen Appoints Robert Hopkins As Chief Medical Officer
5/23/2022 6:57:19 AM Ocugen Says FDA Lifts Clinical Hold On Company's Phase 2/3 Clinical Trial, OCU-002, For COVAXIN
4/25/2022 7:37:54 AM Ocugen Announces Positive DSMB Recommendation For OCU400-101 Clinical Trial
3/23/2022 8:03:02 AM Ocugen Appoints Marna Whittington To Board
3/4/2022 7:20:00 AM Ocugen Says FDA Declines EUA For COVAXIN For Active Immunization To Prevent COVID-19 In Ages 2 To 18
2/22/2022 10:12:30 PM Ocugen Announces Pricing Of $53.5 Mln Public Offering Of Common Stock
12/30/2021 10:06:47 AM Bharat Biotech Reports Positive Data From COVAXIN, COVID-19 Candidate Vaccine, In Children 2- 18 Yrs